Metsera is on the rise with Novo Nordisk.

Metsera, Inc. (NASDAQ:MTSR) continues to attract investors' attention. On Tuesday, this stock reached an all-time high after Novо Nordisk raised its $10 billion acquisition offer from Pfizer Inc..

During intraday trading, Metsera reached a new 52-week peak at $74.24 and closed the day at $73.18, up by 20.50%.

Earlier in the day, Novо Nordisk announced that it had enhanced its $10 billion offer for Metsera. Metsera stated that Pfizer’s $7 billion proposal was "superior." Notably, Pfizer had received approval for a merger plan with Metsera last month.

In Novо Nordisk’s updated offer, Metsera, Inc.’s outstanding common shares will be acquired at a price of $62.20 per share, with additional value rights of $24 based on specific clinical and regulatory successes.

On Tuesday, Pfizer filed two lawsuits against the controlling shareholders of Novо Nordisk and Metsera. The lawsuit alleged that Novо Nordisk engaged in "anti-competitive behavior" and acted to maintain its dominance in the GLP-1 market.

Pfizer stated that it plans to take all necessary measures to block the advance of Novо Nordisk’s anti-competitive proposed transaction.

We recognize the potential of MTSR as an investment, but we believe that some artificial intelligence (AI) stocks offer greater promises of higher returns and limited downside risk. If you are looking for an undervalued AI stock that stands to benefit significantly from Trump tariffs and localization, check out our free report on the best short-term AI stock.